→
iShares Nasdaq Biotechnology ETF
iShares Nasdaq Biotechnology ETF (IBB) is currently trading at $169.37, down 1.62% from its previous close of $172.16, reflecting market volatility. The ETF has seen a 52-week high of $179.64 and a low of $107.43, indicating a wide trading range that suggests uncertainty in the biotech sector. Given the beta of 0.79, IBB shows lower volatility compared to the market, but the recent headlines highlight mixed sentiment towards biotechnology, keeping the outlook neutral.
Hold IBB as the outlook remains uncertain amid mixed sentiment in the biotechnology sector.
Concerns Shift From Obsolescence To Oil
2026-04-09
Amgen Posts 77% Response In Thyroid Eye Disease Study
2026-04-06
Biotech Is Holding Steady In 2026
2026-04-02
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes your holdings, and delivers actionable intelligence weekly.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Helm's AI rates IBB as Neutral. Hold IBB as the outlook remains uncertain amid mixed sentiment in the biotechnology sector.
Conversely, if market conditions worsen or if there are significant regulatory challenges in biotech, IBB could retest its 52-week low of $107.43, indicating a downside risk of 36.5%. The recent headlines reflect concerns in the sector, which could lead to further volatility.
If the biotech sector continues to recover, IBB could rebound towards its 52-week high of $179.64, representing a potential upside of 6.1%. Positive developments in biotech, like Amgen's 77% response in thyroid eye disease studies, could further boost investor confidence.
iShares Nasdaq Biotechnology ETF (IBB) is currently trading at $169.37, down 1.62% from its previous close of $172.16, reflecting market volatility. The ETF has seen a 52-week high of $179.64 and a low of $107.43, indicating a wide trading range that suggests uncertainty in the biotech sector. Given the beta of 0.79, IBB shows lower volatility compared to the market, but the recent headlines highlight mixed sentiment towards biotechnology, keeping the outlook neutral.
iShares Nasdaq Biotechnology ETF (IBB) is currently trading at $169.37, down 1.62% from its previous close of $172.16, reflecting market volatility. The ETF has seen a 52-week high of $179.64 and a low of $107.43, indicating a wide trading range that suggests uncertainty in the biotech sector. Given the beta of 0.79, IBB shows lower volatility compared to the market, but the recent headlines highlight mixed sentiment towards biotechnology, keeping the outlook neutral. Our overall verdict is Neutral.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for IBB at helmterminal.dev/analyze/IBB, updated continuously during US market hours. No signup required.